PORTLAND, Ore., June 14, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, Inc. announced today that the results of the clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder (PD) were published in Journal of Translational Medicine.
The study evaluated 81 patients suffering with PD, with and without other psychiatric comorbidities, which were treated with NBTX-001, an inhalational gas mixture containing noble gas xenon. After the completion of treatment both groups were found to have a dramatic reduction in the incidence of panic attacks, the effect that was sustained during the six months of study follow up. In addition, patients with concomitant anxiety and depression were found to have a substantial decrease in symptom severity. The treatment was very well tolerated with only minimal side effects reported in the minority of patients.
Current treatment options for PD include antidepressants and benzodiazepine tranquilizers, which have limited efficacy, numerous adverse side effects, and treat only the symptoms of the disease.
“While we realize the limitations of the open label design of our study, we are very encouraged by the potent signals of efficacy that it has demonstrated,” said Dr. Vlad Bogin, CEO of Nobilis Therapeutics. “This study validates company’s methodology and paves the way to the upcoming studies of NBTX-001 in post-traumatic stress disorder (PTSD) and in other psychiatric and neurodegenerative diseases.”
“I am delighted to have the opportunity to share these clinical data in a peer-reviewed publication,” said Dr. Alexander Dobrovolsky who was the principle investigator in the study. “Now, that we have validated our approach in a controlled study setting, we are looking forward to conducting randomized, placebo-controlled trials in a number of very promising indications.”
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have an exceptional safety profile proven by decades of clinical use. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric and neurodegenerative diseases and leverages the experience of its international team that has successfully used this technology in the treatment of over 500 patients for conditions ranging from panic attacks to substance abuse.
Contact: Vlad Bogin, MD, FACP 3042NW Monte Vista Terrace Portland, OR 97210 Tel: (971) 229-1679 Email: vbogin(at)nobilistx(dot)com Website: http://www.nobilistx.com Twitter: @nobilistx